Global Obesity Treating Neuromodulation System 麻豆原创 Research Report 2024

Publication ID:

PB503244556

Publication Date:

March 15, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Medical Devices [2]

Pharma & Healthcare [3]

Description:

Neuromodulation has shown some benefit in treatment of obesity and it is less invasive than the gastric banding and gastric bypass, which are surgical treatment option for obesity. Obesity treating neuromodulation system works by manipulation the appetite signal between gut and the brain.
The global Obesity Treating Neuromodulation System market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North America region dominates the global obesity treating neuromodulation system market and is expected to continue to dominate the market over the forecast period. High adoption of neuromodulation system and increased regulatory approval of these devices in the region is expected to be factor for the growth of obesity treating neuromodulation system market. Europe is the second biggest market for the obesity treating neuromodulation system. Increasing prevalence of obesity and presence of market players is also driving the market of obesity treating neuromodulation system market in North America and Europe.
This report aims to provide a comprehensive presentation of the global market for Obesity Treating Neuromodulation System, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Obesity Treating Neuromodulation System.
Report Scope
The Obesity Treating Neuromodulation System market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Obesity Treating Neuromodulation System market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Obesity Treating Neuromodulation System manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Medtronic
Cyberonics
Abbott
BioControl Medical
Leptos Medical
ReShape Lifesciences
Nevro
Nuvectra
Segment by Type
Vagus Nerve Stimulator
Splanchnic Nerve Stimulator
Deep Brain Stimulator
Spinal Cord Stimulator
Autonomous Nerve Stimulator
Others
Segment by Application
Hospitals
Clinics
Ambulatory Surgical Centers
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Obesity Treating Neuromodulation System manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Obesity Treating Neuromodulation System in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Obesity Treating Neuromodulation System 麻豆原创 Overview
1.1 Product Overview and Scope of Obesity Treating Neuromodulation System
1.2 Obesity Treating Neuromodulation System Segment by Type
1.2.1 Global Obesity Treating Neuromodulation System 麻豆原创 Value Comparison by Type (2024-2030)
1.2.2 Vagus Nerve Stimulator
1.2.3 Splanchnic Nerve Stimulator
1.2.4 Deep Brain Stimulator
1.2.5 Spinal Cord Stimulator
1.2.6 Autonomous Nerve Stimulator
1.2.7 Others
1.3 Obesity Treating Neuromodulation System Segment by Application
1.3.1 Global Obesity Treating Neuromodulation System 麻豆原创 Value by Application: (2024-2030)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Centers
1.4 Global Obesity Treating Neuromodulation System 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Obesity Treating Neuromodulation System Revenue 2019-2030
1.4.2 Global Obesity Treating Neuromodulation System Sales 2019-2030
1.4.3 Global Obesity Treating Neuromodulation System 麻豆原创 Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Obesity Treating Neuromodulation System 麻豆原创 Competition by Manufacturers
2.1 Global Obesity Treating Neuromodulation System Sales 麻豆原创 Share by Manufacturers (2019-2024)
2.2 Global Obesity Treating Neuromodulation System Revenue 麻豆原创 Share by Manufacturers (2019-2024)
2.3 Global Obesity Treating Neuromodulation System Average Price by Manufacturers (2019-2024)
2.4 Global Obesity Treating Neuromodulation System Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Obesity Treating Neuromodulation System, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Obesity Treating Neuromodulation System, Product Type & Application
2.7 Obesity Treating Neuromodulation System 麻豆原创 Competitive Situation and Trends
2.7.1 Obesity Treating Neuromodulation System 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Obesity Treating Neuromodulation System Players 麻豆原创 Share by Revenue
2.7.3 Global Obesity Treating Neuromodulation System 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Obesity Treating Neuromodulation System Retrospective 麻豆原创 Scenario by Region
3.1 Global Obesity Treating Neuromodulation System 麻豆原创 Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Obesity Treating Neuromodulation System Global Obesity Treating Neuromodulation System Sales by Region: 2019-2030
3.2.1 Global Obesity Treating Neuromodulation System Sales by Region: 2019-2024
3.2.2 Global Obesity Treating Neuromodulation System Sales by Region: 2025-2030
3.3 Global Obesity Treating Neuromodulation System Global Obesity Treating Neuromodulation System Revenue by Region: 2019-2030
3.3.1 Global Obesity Treating Neuromodulation System Revenue by Region: 2019-2024
3.3.2 Global Obesity Treating Neuromodulation System Revenue by Region: 2025-2030
3.4 North America Obesity Treating Neuromodulation System 麻豆原创 Facts & Figures by Country
3.4.1 North America Obesity Treating Neuromodulation System 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Obesity Treating Neuromodulation System Sales by Country (2019-2030)
3.4.3 North America Obesity Treating Neuromodulation System Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Obesity Treating Neuromodulation System 麻豆原创 Facts & Figures by Country
3.5.1 Europe Obesity Treating Neuromodulation System 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Obesity Treating Neuromodulation System Sales by Country (2019-2030)
3.5.3 Europe Obesity Treating Neuromodulation System Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Obesity Treating Neuromodulation System 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Obesity Treating Neuromodulation System 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Obesity Treating Neuromodulation System Sales by Country (2019-2030)
3.6.3 Asia Pacific Obesity Treating Neuromodulation System Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Obesity Treating Neuromodulation System 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Obesity Treating Neuromodulation System 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Obesity Treating Neuromodulation System Sales by Country (2019-2030)
3.7.3 Latin America Obesity Treating Neuromodulation System Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Obesity Treating Neuromodulation System 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Obesity Treating Neuromodulation System 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Obesity Treating Neuromodulation System Sales by Country (2019-2030)
3.8.3 Middle East and Africa Obesity Treating Neuromodulation System Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Obesity Treating Neuromodulation System Sales by Type (2019-2030)
4.1.1 Global Obesity Treating Neuromodulation System Sales by Type (2019-2024)
4.1.2 Global Obesity Treating Neuromodulation System Sales by Type (2025-2030)
4.1.3 Global Obesity Treating Neuromodulation System Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global Obesity Treating Neuromodulation System Revenue by Type (2019-2030)
4.2.1 Global Obesity Treating Neuromodulation System Revenue by Type (2019-2024)
4.2.2 Global Obesity Treating Neuromodulation System Revenue by Type (2025-2030)
4.2.3 Global Obesity Treating Neuromodulation System Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global Obesity Treating Neuromodulation System Price by Type (2019-2030)
5 Segment by Application
5.1 Global Obesity Treating Neuromodulation System Sales by Application (2019-2030)
5.1.1 Global Obesity Treating Neuromodulation System Sales by Application (2019-2024)
5.1.2 Global Obesity Treating Neuromodulation System Sales by Application (2025-2030)
5.1.3 Global Obesity Treating Neuromodulation System Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global Obesity Treating Neuromodulation System Revenue by Application (2019-2030)
5.2.1 Global Obesity Treating Neuromodulation System Revenue by Application (2019-2024)
5.2.2 Global Obesity Treating Neuromodulation System Revenue by Application (2025-2030)
5.2.3 Global Obesity Treating Neuromodulation System Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global Obesity Treating Neuromodulation System Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Medtronic
6.1.1 Medtronic Corporation Information
6.1.2 Medtronic Description and Business Overview
6.1.3 Medtronic Obesity Treating Neuromodulation System Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Medtronic Obesity Treating Neuromodulation System Product Portfolio
6.1.5 Medtronic Recent Developments/Updates
6.2 Cyberonics
6.2.1 Cyberonics Corporation Information
6.2.2 Cyberonics Description and Business Overview
6.2.3 Cyberonics Obesity Treating Neuromodulation System Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Cyberonics Obesity Treating Neuromodulation System Product Portfolio
6.2.5 Cyberonics Recent Developments/Updates
6.3 Abbott
6.3.1 Abbott Corporation Information
6.3.2 Abbott Description and Business Overview
6.3.3 Abbott Obesity Treating Neuromodulation System Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Abbott Obesity Treating Neuromodulation System Product Portfolio
6.3.5 Abbott Recent Developments/Updates
6.4 BioControl Medical
6.4.1 BioControl Medical Corporation Information
6.4.2 BioControl Medical Description and Business Overview
6.4.3 BioControl Medical Obesity Treating Neuromodulation System Sales, Revenue and Gross Margin (2019-2024)
6.4.4 BioControl Medical Obesity Treating Neuromodulation System Product Portfolio
6.4.5 BioControl Medical Recent Developments/Updates
6.5 Leptos Medical
6.5.1 Leptos Medical Corporation Information
6.5.2 Leptos Medical Description and Business Overview
6.5.3 Leptos Medical Obesity Treating Neuromodulation System Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Leptos Medical Obesity Treating Neuromodulation System Product Portfolio
6.5.5 Leptos Medical Recent Developments/Updates
6.6 ReShape Lifesciences
6.6.1 ReShape Lifesciences Corporation Information
6.6.2 ReShape Lifesciences Description and Business Overview
6.6.3 ReShape Lifesciences Obesity Treating Neuromodulation System Sales, Revenue and Gross Margin (2019-2024)
6.6.4 ReShape Lifesciences Obesity Treating Neuromodulation System Product Portfolio
6.6.5 ReShape Lifesciences Recent Developments/Updates
6.7 Nevro
6.6.1 Nevro Corporation Information
6.6.2 Nevro Description and Business Overview
6.6.3 Nevro Obesity Treating Neuromodulation System Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Nevro Obesity Treating Neuromodulation System Product Portfolio
6.7.5 Nevro Recent Developments/Updates
6.8 Nuvectra
6.8.1 Nuvectra Corporation Information
6.8.2 Nuvectra Description and Business Overview
6.8.3 Nuvectra Obesity Treating Neuromodulation System Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Nuvectra Obesity Treating Neuromodulation System Product Portfolio
6.8.5 Nuvectra Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Obesity Treating Neuromodulation System Industry Chain Analysis
7.2 Obesity Treating Neuromodulation System Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Obesity Treating Neuromodulation System Production Mode & Process
7.4 Obesity Treating Neuromodulation System Sales and 麻豆原创ing
7.4.1 Obesity Treating Neuromodulation System Sales Channels
7.4.2 Obesity Treating Neuromodulation System Distributors
7.5 Obesity Treating Neuromodulation System Customers
8 Obesity Treating Neuromodulation System 麻豆原创 Dynamics
8.1 Obesity Treating Neuromodulation System Industry Trends
8.2 Obesity Treating Neuromodulation System 麻豆原创 Drivers
8.3 Obesity Treating Neuromodulation System 麻豆原创 Challenges
8.4 Obesity Treating Neuromodulation System 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Medtronic
Cyberonics
Abbott
BioControl Medical
Leptos Medical
ReShape Lifesciences
Nevro
Nuvectra

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.